KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $260.0 million.

  • Pfizer's Asset Writedowns and Impairment changed N/A to $260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $697.0 million, marking a year-over-year decrease of 425.82%. This contributed to the annual value of $4.2 billion for FY2024, which is 3156.96% down from last year.
  • Per Pfizer's latest filing, its Asset Writedowns and Impairment stood at $260.0 million for Q3 2025.
  • Pfizer's Asset Writedowns and Impairment's 5-year high stood at $352.0 million during Q4 2023, with a 5-year trough of $24.0 million in Q2 2021.
  • For the 5-year period, Pfizer's Asset Writedowns and Impairment averaged around $180.1 million, with its median value being $200.0 million (2022).
  • Per our database at Business Quant, Pfizer's Asset Writedowns and Impairment soared by 77096.77% in 2023 and then tumbled by 6125.0% in 2025.
  • Pfizer's Asset Writedowns and Impairment (Quarter) stood at $31.0 million in 2021, then surged by 545.16% to $200.0 million in 2022, then skyrocketed by 76.0% to $352.0 million in 2023, then plummeted by 31.82% to $240.0 million in 2024, then increased by 8.33% to $260.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $260.0 million for Q3 2025, versus $93.0 million for Q2 2025 and $344.0 million for Q1 2025.